Thinking of attending Biospain? Why not get the most out of your experience by joining the UK Delegation?🇬🇧🇪🇸 Sign up here biopartner.co.uk/biospain
Don’t miss your opportunity to be a part of the UK Guest Country Delegation at #BioSpain2026! Get your pass today.
EXHIBITORS: Boost your profile at the #Bionow#Neuroscience conference on 9 July, with #exhibitor packages starting at just £450, including 2 delegate passes. Get your company in front of academics, clinicians and industry leaders.
Find out more:
bionow.glueup.com/resources/…
The EMA has updated a series of assessment timetable documents relating to initial marketing authorisation applications. Get in touch to discuss how the updated EMA timetables may affect your strategy: scendea.com/contact
Our Chief Executive Officer Jeremy Skillington & Chief Financial Officer Ian O'Connell will be attending @IAmBiotech Bio International Convention, one of the world’s leading events for the biotechnology and life sciences industry.
📍San Diego, US
🗓️22-25 June 2026
With interim data from the POLB 001 TOPICAL trial expected this summer, alongside the recent Canadian patent grant, momentum continues to build across the programme. The team looks forward to engaging with potential partners at BIO to discuss the clinical progress, our expanding IP portfolio, and broader commercial opportunity ahead.
If you’re attending BIO 2026, connect with our team via the BIOpartnering platform.
Learn more:
convention.bio.org/#POLB#BIO2026#Biotech#LifeSciences#HealthcareInnovation#Biotechnology#Networking#Innovation#BIOInternational
Make the most of #BIO26's advanced rates with an additional $405 off when you register through @BioPartner
Register and save today! biopartner.co.uk/bio
T&Cs apply.
To enhance our expertise in the Cytokine Release Syndrome space we have appointed Dr Adrian Kilcoyne to our Scientific Advisory Board.
Dr Kilcoyne bring over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome.
Adrian’s wealth of experience will provide further support to our established team of experts as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems.
Learn more about Dr Kilcoyne’s experience and read the full announcement here:
londonstockexchange.com/news…#POLB#SAB#ScientificAdvisory#BoardMember#AIM#Cancer#Oncology#ScientificExpert
Develop your leadership and management skills with our 17 free online modules. They share the latest leadership tools to enable you to reflect on and practise new approaches.
Login or register on NIHR Learn to find out more:
learn.nihr.ac.uk/course/view…
The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible.
-
For more information on this guidance, get in touch: scendea.com/contact